TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 13, Issue 1, 2026
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
EFFICACY AND SAFETY OF INTRAVENOUS PAMIDRONATE IN ADULTS WITH OSTEOGENESIS IMPERFECTA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Author
Manjunath C
Email
keyword
Osteogenesis imperfecta, Pamidronate, bone mineral density, fracture rate
Abstract
Osteogenesis imperfecta (OI) is a genetic disease which is rare, has fragile bones, low bone mineral density (BMD) and high tendency to fractures. This study aimed at assessing the effectiveness and safety of intravenous pamidronate in adults with OI. Those with OI were randomly divided into 75 patients with 38 receiving quarterly intravenous pamidronate (treatment group) and 37 were given a placebo (control group) at 36 months. The change in lumbar spine BMD was the main efficacy endpoint, and the secondary efficacy outcomes were changes in BMD at the hip, fracture rate, index of pain, functional mobility, and quality of life (QoL). The measurements of biochemical markers such as serum parathormone (PTH), vitamin D and urinary calcium levels were also taken. The treatment group recorded considerable improvements in lumbar spine BMD (+0.18 0.05 g/cm 2) and hip BMD (+0.12 0.04 g/cm 2) after 36 months as compared to the control group (+0.04 0.02 g/cm 2 and +0.03 0.01 g/cm 2, respectively). Fracture rate in the treatment group was reduced by -0.8 ± 0.6 per annum with a -0.2 ± 0.3 per annum in the control group. The secondary endpoints, such as pain management, functional mobility, and QoL improved significantly in the treatment group. These were reduced serum levels of PTH and an increase in serum vitamin D and urinary calcium excretion. The treatment was tolerable even though mild adverse effects were noted which included nausea, fatigue, and musculoskeletal pain. Finally, pamidronate intravenously is an effective treatment of OI in adults because it enhances bone health, bone fracture, and quality of life.
Download Broucher
Back to Top >>>>